The Clinical Utility and Limitations of Serum Carbohydrate Antigen (CA19-9) as a Diagnostic Tool for Pancreatic Cancer and Cholangiocarcinoma

被引：0
|
作者：
Sundeep Singh
Shou-jiang Tang
Jayaprakash Sreenarasimhaiah
Luis F. Lara
Ali Siddiqui
机构：
[1] Stanford University,Division of Gastroenterology and Hepatology
[2] University of Mississippi,Division of Digestive Diseases
[3] University of Texas-Southwestern Medical Center,Division of Digestive and Liver Diseases
[4] Baylor University Medical Center,Division of Gastroenterology and Hepatology, Jefferson Digestive Disease Institute
[5] Thomas Jefferson University,undefined
来源：
Digestive Diseases and Sciences | 2011年 / 56卷
关键词：
Serum carbohydrate antigen; CA19-9; Pancreatic cancer; Cholangiocarcinoma;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2491 / 2496
页数：5
相关论文
共 50 条
  • [21] Clinical value of serum CA19-9 levels in evaluating resectability of pancreatic carcinoma
    Zhang, Shun
    Wang, Yi-Ming
    Sun, Chuan-Dong
    Lu, Yun
    Wu, Li-Qun
    WORLD JOURNAL OF GASTROENTEROLOGY, 2008, 14 (23) : 3750 - 3753
  • [22] Effects of miR-16 Plus CA19-9 Detections on Pancreatic Cancer Diagnostic Performance
    Gao, Ling
    He, Song-Bing
    Li, De-Chun
    CLINICAL LABORATORY, 2014, 60 (01) : 73 - 77
  • [23] An evaluation of the diagnostic value of CA19-9 and CEA levels in patients with pancreatic cancer
    Zhenhua Ma
    The Journal of Biomedical Research, 2009, (03) : 199 - 202
  • [24] Clinical value of serum CA19-9 levels in evaluating resectability of pancreatic carcinoma
    Shun Zhang
    World Journal of Gastroenterology, 2008, (23) : 3750 - 3753
  • [25] Serum carbohydrate antigen (CA) 19-9 as a prognostic factor in cholangiocarcinoma: A meta-analysis
    Liu S.-L.
    Song Z.-F.
    Hu Q.-G.
    Shan D.
    Hu S.-B.
    Li J.
    Zheng Q.-C.
    Frontiers of Medicine in China, 2010, 4 (4): : 457 - 462
  • [26] Clinical Significance of CA19-9 in the Follow-Up of Colorectal Cancer Patients with Elevated Preoperative Serum CA19-9
    Yang, Shung-Haur
    Jiang, Jeng -Kai
    Chang, Shih-Ching
    Huang, Chi-Jung
    Lin, Jen-Kou
    HEPATO-GASTROENTEROLOGY, 2013, 60 (125) : 1021 - 1027
  • [27] Combination of plasma microRNAs with serum CA19-9 for early detection of pancreatic cancer
    Liu, Jianqiang
    Gao, Jun
    Du, Yiqi
    Li, Zhaoshen
    Ren, Yan
    Gu, Junjun
    Wang, Xiaowei
    Gong, Yanfang
    Wang, Weiwei
    Kong, Xiangyu
    INTERNATIONAL JOURNAL OF CANCER, 2012, 131 (03) : 683 - 691
  • [28] Elevated CEA and CA19-9 serum levels independently predict advanced pancreatic cancer at diagnosis
    van Manen, Labrinus
    Groen, Jesse V.
    Putter, Hein
    Vahrmeijer, Alexander L.
    Swijnenburg, Rutger-Jan
    Bonsing, Bert A.
    Mieog, J. Sven D.
    BIOMARKERS, 2020, 25 (02) : 186 - 193
  • [29] Clinical Utility of the Combined Use of CA19-9 and DUPAN-2 in Pancreatic Adenocarcinoma
    Sumiyoshi, Tatsuaki
    Uemura, Kenichiro
    Shintakuya, Ryuta
    Okada, Kenjiro
    Baba, Kenta
    Harada, Takumi
    Serikawa, Masahiro
    Ishii, Yasutaka
    Nakamura, Shinya
    Arihiro, Koji
    Murakami, Yoshiaki
    Takahashi, Shinya
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (07) : 4665 - 4672
  • [30] Prognostic impact of preoperative NLR and CA19-9 in pancreatic cancer
    Asaoka, Tadafumi
    Miyamoto, Atsushi
    Maeda, Sakae
    Tsujie, Masanori
    Hama, Naoki
    Yamamoto, Kazuyoshi
    Miyake, Masakazu
    Haraguchi, Naotsugu
    Nishikawa, Kazuhiro
    Hirao, Motohiro
    Ikeda, Masataka
    Sekimoto, Mitsugu
    Nakamori, Shoji
    PANCREATOLOGY, 2016, 16 (03) : 434 - 440
12345